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Transposable elements are natural, non-viral gene delivery vehicles ca-
pable of mediating stable genomic integration. The Sleeping Beauty (SB) 
transposon has the ability to cut-and-paste the ‘gene of interest’ into 
the genome, providing the basis for long-term, permanent transgene ex-
pression in transgenic cells and organisms. The SB transposon system is 
relatively well characterized, and has been extensively engineered for 
efficient gene delivery and gene discovery purposes in a wide range of 
vertebrates, including humans. The SB system is a safe and simple-to-use 
vector that enables cost-effective, rapid preparation of therapeutic doses 
of cell products. Recently, there has been a growing interest in using the 
SB system for therapy as evidenced by the large number of pre-clinical 
studies. SB moved swiftly from pre-clinical to clinical trials in almost a 
decade. In this article, we highlight the advancements and challenges as-
sociated with the SB system in various therapeutic applications. We also 
provide an overview that has been exploited by spin-off companies based 
on the SB system. 
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The high expectation on gene ther-
apy continues to grow, as it holds 
the potential to provide a cure for 
myriad genetic diseases by sub-
stituting a corrupted gene with 
the respective functional one to 
achieve a therapeutic effect. The 
success of gene therapy is mainly 
dependent on the safety, efficacy, 
simplicity, cost-effectiveness and 
scalability of the vector system used 
for delivering and expressing the 
therapeutic gene of interest (GOI) 
into the cells. The numerous gene 
delivery approaches can be broad-
ly classified as viral and non-viral 
mediated (Figure 1). Viral vectors 
have been exploited for clinical 
use based on their inherent gene 
delivery capabilities in multiple 
cell types. In fact, the majority of 
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the gene therapy clinical trials cur-
rently use viral vectors. Currently, 
there are around 600 and 800 gene 
therapy clinical trials involving ret-
ro/lentiviral and AV/AAV vectors, 
respectively [1]; however, despite 
their superb delivery capacity, vi-
ral vectors do have certain limita-
tions. Whilst AV and AAV vectors 
are excellent delivery/expression 
vectors in non-dividing cells, they 
are diluted out by cell division. To 
achieve long-term therapeutic effect 
in dividing cells, multiple doses of 
administration are required, which 
induces adverse immune responses 
[2,3]. AAVs are also limited by their 
relatively low packaging capacity 
(<5 kb). By contrast, both retrovi-
ral and lentiviral vectors have the 
 f FIGURE 1
Different gene delivery systems for gene therapy.
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Gene therapy involves delivery of the gene of interest into therapeutically relevant cells. The delivery can be accomplished by several 
gene delivery systems as summarized in the graphic. Viruses possess the inherent ability to infect and deliver DNA into a wide variety of 
cell types. This phenomenon has been exploited for various gene therapy applications. Based on the integration ability viral vectors can 
be further classified into integrating and non-integrating vectors. Non-integrating viral vectors include vectors from adeno-associated 
virus (AAV), adenovirus (AV), herpes simplex virus 1 amplicon (HSV-1) and baculovirus (Baculo); while integrating viral vectors are 
derived from lentivirus and retrovirus. Because of the associated disadvantages with viral vectors, recently non-viral vectors have 
gained significance as an alternative delivery method. Naked DNA can be delivered either by transfection or nucleofection or can be 
complexed with liposomes and nanoparticles. However, these methods have a limitation of mediating the transient effect, due to the 
lack of stable genome integration. However, natural gene delivery vehicles like Sleeping Beauty and PiggyBac transposons can overcome 
the problem of transient expression. Transposons have the inherent ability to stably integrate the gene of interest into the genome, 
providing long term or possibly permanent therapeutic effect. Sleeping Beauty transposon system has been combined with both non-
viral and viral delivery techniques (orange dotted line).  
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capacity to mediate stable integra-
tion of the GOI, resulting in stable 
expression of the therapeutic gene. 
While lentiviruses have the capacity 
to infect both non-dividing and di-
viding cells, retroviruses such as the 
Moloney murine leukemia virus 
(MoLV) are restricted to dividing 
cells [4]. MoLV prefers to integrate 
into transcription start sites, where-
as lentiviral vectors based on HIV 
exhibit bias towards integration 
into active genes [5]. Due to their 
biased integration pattern, retro- 
and lenti-viral vectors are associ-
ated with an elevated risk of both 
insertional mutagenesis and trans-
activation of oncogenes around the 
integration site [6,7]. Finally, viral 
production methods are complex, 
and generally involve high costs, 
partially associated with regulatory 
issues. 
In contrast to viral vectors, 
non-viral vectors have been con-
sidered for their simplicity, safety 
and ease of production. Non-vi-
ral approaches include physical or 
chemical delivery methods such 
as transfection, electroporation/
nucleofection, gene gun and nan-
odelivery. The bottleneck problems 
of classical non-viral delivery are its 
low efficacy and transient nature. 
However, there are currently over 
400 non-viral gene therapy clinical 
trials [1]. 
Mobile genetic elements (trans-
posons) are natural gene delivery 
vehicles capable of genomic in-
sertion. DNA transposons have 
the ability to transpose within the 
genome by a cut-and-paste pro-
cess; however, this process can 
be restricted to a single excision 
event from a transfected plasmid 
to the genome. Stable genomic 
integration provides the basis for 
permanent transgene expression 
in transgenic cells and organisms, 
thereby addressing the bottleneck 
problem of classical non-viral de-
livery. Sleeping Beauty (SB) is a 
resurrected, synthetic transposon, 
belonging to the Tc1/mariner fam-
ily of transposons that is active in 
a wide variety of vertebrates, in-
cluding human cells [8,9]. The po-
tential of the SB-based non-viral 
integrating system as an alternative 
to viral vectors has been thoroughly 
investigated in the last two decades. 
The studies demonstrated its ability 
to mediate long-term gene expres-
sion in various human cell types, 
and revealed several advantageous 
safety features. Currently, the SB 
transposon vector is the most wide-
ly used alternative gene carrier to 
integrating viral vectors.
THE SB TRANSPOSON 
SYSTEM
Generally a transposon system in-
cludes a transposon and a trans-
posase. The transposon acts as a 
carrier, which carries the gene to 
be inserted into the genome. The 
transposase is the workhorse cata-
lyzing the process of transposition. 
Naturally, the transposase is locat-
ed between the inverted terminal 
repeats (ITRs) of the transposon. 
Importantly, however, the trans-
posase gene can be replaced with 
any GOI, and the transposase can 
govern transposition events when 
encoded by a separate plasmid 
in trans. Physical separation of the 
transposon from the transposase 
enabled optimization of trans-
poson versus transposase ratio, 
and also provided the freedom of 
supplying the transposase in the 
form of mRNA, instead of DNA 
[10]. Both components of the SB 
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system, the transposon and the 
transposase, have been extensively 
engineered to improve transposi-
tional activity. 
Engineering the SB 
transposon
SB represents the first functionally 
active DNA transposon in verte-
brates [8]. SB was engineered from 
ancient Tc1/mariner transposon 
fossils found within the Salmonid 
genomes by in vitro evolution [8]. 
The ITRs (230 bp) contains imper-
fect direct repeats (DRs) of 32 bp 
in length that serve as recognition 
signals for the transposase. Binding 
affinity and spacing between the DR 
elements within ITR has been crucial 
for efficient transpositional activities, 
suggesting that a constrained geom-
etry is required during the pre-inte-
gration complex assembly [11,12]. 
Optimizing nucleotide residues (in-
cluding mutations, deletions and 
additions) within the ITRs of the 
original SB transposon (pT) result-
ed in improved transposon versions, 
such as pT2, pT3, pT2B and pT4 
(Table  1). For convenience of use, a 
whole series of transposon vectors 
with different reporter and selection 
markers are available [13].
Engineering the SB 
transposase
The SB transposase is a 39 kDa pro-
tein that possess DNA binding do-
mains, a nuclear localization signal 
(NLS) and the catalytic domain, 
featured by a conserved amino acid 
motif (DDE). Various screens mu-
tagenizing the primary amino acid 
sequence of the SB transposase re-
sulted in hyperactive transposase 
versions (Table 2). SB100X is 100-
fold hyperactive compared to the 
originally resurrected transposase 
(SB10) in certain cell types [13,14].
Mechanism of transposition
Transposition is a relatively 
well-characterized process, divid-
ed into excision and integration 
steps (Figure  2). First, the trans-
posase recognizes the transposon, 
and binds the ITRs. During syn-
aptic complex formation, the 
transposon ends are brought to-
gether by transposase monomers 
(presumably forming a tetramer) 
[15]. The transposase generates a 
DNA double-strand break upon 
excision [16], while single-strand-
ed gaps at the integration site. The 
pre-integration complex contain-
ing the transposon bound trans-
posase performs the integration 
into the host genome. SB trans-
position is a highly coordinated 
reaction that efficiently filters out 
abnormal, toxic transposition 
intermediates [12,17]. Excision 
leaves a footprint (3 bp) at the do-
nor site. Integration occurs into 
TA dinucleotides of the genome, 
and results in target site duplica-
tions, generated by the host repair 
machinery [16,18,19]. Overall, SB 
appears to possess a nearly unbi-
ased, close-to-random integration 
profile [20]. Transposon integra-
tion can be artificially targeted 
(~10%) to a predetermined ge-
nomic locus [20–24].
Several host factors of SB trans-
position, including HMGXB4, 
HMGB1, BANF1, KU70 and 
MIZ-1 have been identified 
[16,17,25–27]. These factors phys-
ically interact with the SB trans-
posase, and assist in different steps 
of the transposition reaction. In 
addition to host encoded cellular 
factors, certain conditions (e.g., se-
rum starvation, DNA methylation) 
are reported to affect SB transposi-
tion [27,28].
  f TABLE 1
List of currently available 
SB transposon vectors.
No. Transposon Ref.
1 pT [8]
2 pT2 [11]
3 pT3 [108]
4 pT2B [15] 
5 pT4 [52] 
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SALIENT FEATURES 
OF SB TRANSPOSON 
TECHNOLOGY
Since its establishment, the SB 
transposon technology has been 
exploited for various applications, 
including gene delivery and gene 
discovery in diverse species. Recent-
ly, it has been intensively exploited 
for human therapeutic applications. 
The SB technology exhibits several 
advantageous features:
 f Non-viral: the GOI can be easily 
cloned between the ITRs of the 
transposon, which can be simply 
co-delivered with the transposase 
in the form of plasmids (or 
plasmid/mRNA). Such procedures 
can be performed in biosafety 
level 1 (BSL-1) laboratory, not 
requiring any complex biohazard 
containment facilities;
 f Well-characterized: the 
transposition mechanism of the 
SB system and its interaction 
with the host is relatively well 
characterized; 
 f Economical: in comparison to the 
production cost of viral vectors, 
Good Manufacturing Practice 
(GMP) grade plasmid production 
is relatively cheap, fast and less 
labor intense;
 f Efficient and stable transgene 
expression: the hyperactive SB 
system has been demonstrated 
to support efficient and stable 
gene expression in various cell 
types. While the SB vector is not 
resistant to silencing (primarily 
dependent on the cargo), the 
expressed integration loci would 
faithfully produce the transgenic 
gene product long-term;
 f Wide range of cell types: SB is 
capable of transposing in a wide 
variety of cell types, including 
therapeutically relevant primary 
cells [9];
 f Not restricted to cycling cells: 
SB is able to transpose in non-
dividing primary cells [29];
 f Transgene integration is 
not restricted to efficient 
homologous recombination (HR): 
the transposase is capable of 
performing efficient transgene 
integration in cells, where the 
homologous recombination 
pathway of the host repair 
machinery is barely active;
 f Maintains intact transgene 
structure: the SB vector is suitable 
to faithfully express complex 
transgenes;
 f Cargo capacity: Although SB 
transposition is most optimal up 
to ~7.5 kb [9] of the transposon, 
the sandwich version (SA) 
has been shown to efficiently 
deliver cargos of >10 kb, thereby 
extending the cloning capacity 
of SB-based vectors. When 
combined with bacterial artificial 
chromosome (BACs), SB can 
deliver transgenes up to 100 kb 
[30];
 f FIGURE 2
Sleeping Beauty transposition.
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During SB transposition, the transposon unit with the inverted terminal repeats (ITRs) 
carrying the gene of interest is excised from the transposon vector by the transposase 
protein (red pie labeled as SB). The excised transposon is then integrated in the genome 
by the bound transposase protein. 
  f TABLE 2
List of currently available SB transposases.
Transposase Ref.
SB10 [8]
SB11 (3-fold higher than SB10) [109]
SB12 (4-fold higher than SB10) [66]
HSB1–HSB5 (up to 10-fold higher than SB10) [108]
HSB13–HSB17 (HSB17 is 17-fold higher than SB10) [111]
SB100X (100-fold higher than SB10) [14]
SB150X (130-fold higher than SB10) [24]
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 f Unbiased, close-to-random 
integr ation profile: the close-
to-random integration profile 
of SB was confirmed by multiple 
studies, and was reported from 
various organisms and cell types 
[20,23,24,31–35];
 f Benign promoter/enhancer 
activity: the SB ITRs have 
negligible intrinsic promoter 
activity (less than ~100-fold vs 
MoMLV);
 f Low immunogenicity: as 
the transposase is provided 
separately from the integrating 
transposon vector, it is present 
only temporarily in the cells. 
Thus, the non-viral transposon 
system generally does not trigger 
adverse immune responses that 
are observed with certain viral 
vectors (AV, AAV);
 f No cross-mobilization in the 
human genome. None of the 
human genes are reported to 
recognize and mobilize the SB 
transposon (in contrast to the 
piggyBac [36,37]). 
CURRENT APPLICATIONS 
OF SB TRANSPOSON 
TECHNOLOGY 
The SB transposon system has 
been used for diverse genetic ap-
plications in vertebrate species, 
which can be broadly classified as 
 f FIGURE 3
Applications of Sleeping Beauty transposon technology.
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The SB transposon system has been successfully used for gene delivery (gene of interest) 
into a variety of animal models and cell types, including stem cells and primary cells 
(both in vitro and in vivo). It has been extensively exploited as a mutagenic tool for gene 
discovery applications. The approach of a forward genetic screen for modeling different 
cancers in animal models led to the discovery of numerous novel genes associated with 
cancer (functional oncogenomics). It has been used also a valuable tool in germline 
transgenesis in various animal species (generating transgenic animals). The SB gene 
delivery technology has been thoroughly used in several pre-clinical studies to model 
wide range of metabolic disorders, degenerative diseases and cancers. In addition, the 
SB system has also been utilized for mapping chromatin landscape, epigenome and 
3D genome organization. Currently it is being evaluated in clinical trials as a non-viral 
gene delivery vector for various gene therapy applications like cancer immunotherapy, 
Alzheimer’s disease and age-related macular degeneration (AMD), all of which involves 
ex vivo modification of patient cells. The chart represents the distribution of various 
therapeutic applications of SB system that are categorized based on the approximate 
number of original research articles published as of March, 2017. 
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gene delivery and discovery (Fig-
ure 3) [38]. Briefly, the SB system 
has been used to generate stable 
transgenic cell clones in tissue 
culture [39] (reviewed in [40]). 
SB has been also highly valuable 
in generating transgenic animals, 
including fish, frog, rat, mouse, 
rabbit, pig, cow and sea squirt (for 
a recent review see [41]). Impor-
tantly, the SB-based transgenic 
technology is able to address pre-
vious problems of transgenesis, 
such as low efficacy, mosaicism, 
unstable gene expression [42], and 
offers novel ways for genetic engi-
neering of even large animals [43]. 
SB was successfully employed in 
reprogramming somatic cells into 
induced pluripotent stem cells 
(iPSCs) that can be expanded and 
differentiated into different cell 
types [44–47]. The SB-based pro-
tocol has also been used for the 
production of iPSCs in various an-
imal models [48–50]. In combina-
tion with an LTR7-based reporter, 
the SB system is suitable for ge-
netic and phenotypic tagging to 
enrich embryonic stem and iPSC 
cultures for naive-like human 
pluripotent stem cells [51,52]. 
Furthermore, SB-based genetic 
screens have been used for gene 
annotation in both germline and 
somatic cells [53–55]. In somatic 
cells, SB is primarily employed in 
functional oncogenomics to iden-
tify novel genetic drivers of can-
cers [41,56,57]. SB has been also 
exploited in dissecting the regu-
latory architecture of the genome 
[58,59]. Nevertheless, it is beyond 
the scope of this review to provide 
comprehensive overview of all the 
various applications of the SB sys-
tem, and readers are referred to 
the recent review articles. 
TAILORING THE SB  
TRANSPOSON  
TECHNOLOGY FOR  
CLINICAL APPLICATIONS
Here we provide an update on the 
cell and gene therapy applications. 
In the last decade, SB-based deliv-
ery vectors have been extensively 
used in pre-clinical animal models 
(for reviews see [38,60–63]). The en-
couraging pre-clinical results fueled 
its promotion towards clinical tri-
als, and currently the technology is 
being evaluated to treat human dis-
eases including cancer (lymphoma) 
(Figure 4), Alzheimer’s disease (AD) 
(Figure 5) and age-related macular 
degeneration (AMD) (Figure 6). The 
preliminary results support further 
clinical development of SB-based 
gene therapy approach. 
The hyperactive SB  
transposon system
The latest optimized version of the 
SB system comprises of the hyper-
active SB100X transposase and 
the pT4 transposon [12,14]. The 
SB100X, generated by molecular 
evolutionary strategy performs 
with significantly higher efficien-
cy of genomic integration that in 
certain cells is even comparable 
to viral performances [14]. Since 
SB100X can integrate the thera-
peutic gene more efficiently, rela-
tively lower amounts of DNA are 
required to achieve similar results 
compared to the less hyperactive 
versions [64]. Importantly, proto-
cols optimized for non-hyperac-
tive transposase versions need to 
be re-optimized to avoid unnec-
essarily high number of integrat-
ed copies of the therapeutic gene. 
The hyperactive transposon ver-
sion, pT4 has optimized substrate 
recognition [12]. 
CELL & GENE THERAPY INSIGHTS 
138 DOI: 10.18609/cgti.2017.014
Switch from DNA to mRNA 
as a source of transposase 
Electroporation/nucleofection of 
plasmid DNA can be highly toxic to 
certain cells, including primary stem 
cells [64]. By contrast, nucleofection 
of RNA is not significantly more 
toxic than the nucleofection alone, 
indicating that the toxicity is not 
caused by nucleofecting nucleic acid 
per se. Thus, switching the trans-
posase source from plasmid DNA to 
mRNA could mitigate the toxicity of 
the delivery. Furthermore, supplying 
 f FIGURE 4
Clinical application of Sleeping Beauty transposon technology for cancer immunotherapy.
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Sleeping Beauty system has been successfully used in the clinical trials for engineering T cells to express chimeric antigen receptor 
(CAR) for use against leukemias and lymphomas. SB-modified T cells were used for autologous or allogeneic hematopoietic stem-cell 
transplantation (HSCT). Shown here is a schematic depicting the autologous cancer immunotherapy involving engineering patient’s own 
cells to recognize antigens presented by cancer cells and destroy them. The illustration shows chimeric antigen receptor (CAR)-T-cell-
based adoptive immunotherapy for hematological malignancy. Peripheral blood CD4+ T cells isolated from the patient’s blood that are 
genetically modified using the SB system. The engineered cells express relevant cell surface CAR that can recognize the surface antigens 
of malignant cells. To generate sufficient number of engineered cells for clinical application the CAR-modified T-cells are subjected to ex 
vivo expansion, and then infused back into the respective patient where tumor cells are recognized and killed by CAR+ T-cells.
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the transposase as mRNA would 
ensure its transient expression, and 
decrease the risk of remobilization of 
the integrated therapeutic gene (safe-
ty concern) [10]. 
Extending the cloning 
capacity of the SB-based 
vector: the SA transposon 
The transposition efficiency of SB is 
inversely correlated with the actual 
size of the transposon over 7.5 kb [9]. 
The ‘sandwich’ (SA) configuration of 
the transposon was aimed to improve 
the mobilization of larger cargos. 
The SA transposon consists of four 
ITRs in total, with two complete 
elements flanking the GOI in an 
inverted orientation (Figure 7). Such 
an arrangement of a Tc1-like trans-
poson was observed to mobilize large 
(>10kb) pieces of genomic DNA in 
 f FIGURE 5
Gene therapy approach utilizing Sleeping Beauty transposon technology for the development of encapsu-
lated cell biodelivery (ECB) device for Alzheimer’s disease (AD).
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Illustration of ECB device for AD: Human retinal pigment epithelial cells (ARPE-19) are genetically engineered using the Sleeping 
Beauty system to express nerve growth factor (NGF). Engineered cells are encapsulated into an implant (semi-permeable hollow 
fiber membrane that allows the influx of nutrients and the efflux of NGF) providing an internal cell-supportive scaffold matrix for cell 
adherence and survival. The implant was validated by placing them in sterile containers filled with serum-free medium at 37 °C for 
up to 4.5 weeks. The validated implants are surgically implanted into the basal forebrain of AD patients. The cells are protected from 
immune rejection by the semipermeable membrane, and thus no immunosuppression is required during the treatment. The implanted 
ECB device secretes NGF that can arrest and might reverse the degeneration of the basal forebrain cholinergic neurons (as shown in 
the adjoining inlet at the bottom).
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 f FIGURE 6
Gene therapy approach utilizing Sleeping Beauty transposon technology for the treatment of exudative 
age-related macular degeneration (AMD).
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Exudative AMD involves degeneration of retinal pigment epithelial (RPE) cells due to extensive neovascularization resulting from 
imbalanced concentration of intraocular proteins like vascular endothelial growth factor (VEGF) and Pigment Epithelium-Derived Factor 
(PEDF). Illustration of gene therapy approach for AMD: Patient’s own RPE cells are surgically isolated from the biopsy and genetically 
engineered using the Sleeping Beauty system to express PEDF. Engineered cells are transplanted back into the same patient swiftly in a 
short span of time (approximately 1 hour). Secreted PEDF protein interacts with its receptor and triggers an anti-angiogenic cascade 
that suppresses the neovascularization and mitigates retinal damage (as shown in the adjoining inlet at the bottom). Overexpression of 
PEDF restores the balance between PEDF and VEGF protein concentrations.
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Drosophila [65]. Indeed, translating 
this observation to SB technology 
yielded the SA transposon with a 
superior ability to transpose >10 kb 
transgenes [66,67].
Shielding the transposon 
delivered transgene  
cassettes with insulators
SB facilitates the transgene expres-
sion in a copy-number dependent 
manner in transgenic animals, sug-
gesting that the SB vector does not 
particularly alert the silencing ma-
chinery of the host [42]. Thus, in-
corporating insulator sequences in 
the SB-based vector might not be 
necessary to protect the transgene 
expression from silencing. On the 
other side, use of insulators mo-
tifs was demonstrated to effectively 
shield the promoter activity of the 
transgene cassette at the integration 
locus [26,68]. However, while insu-
lators could prevent the transactiva-
tion of oncogenes, inserting insula-
tor motifs could also have undesired 
effect on genome structure. Thus, 
the potential risks and benefits of 
using insulator sequences need to 
be carefully evaluated. 
Delivery of the SB  
transposon system
Several non-viral gene delivery strat-
egies have been tested for delivering 
SB constructs in vitro. In hard-to 
transfect cell types electroporation/
nucleofection appears to be the 
most effective. A current limitation 
of this strategy for clinical applica-
tions is its capacity to engineer low 
number of cells. In principle, a flow 
through electroporation strategy 
could be beneficial to increase the 
number of engineered cells. 
Besides nucleofection, nanopar-
ticle-like carriers proved to be 
efficient to deliver the SB system. 
Notably, these carriers are also suit-
able to be combined with various 
targeting molecules that allow cell 
type specific transfer. In one exam-
ple, hard-to-transfect mesenchymal 
stem cells (MSCs) could be targeted 
with high efficacy (∼52%) by using 
engineered lipid-based nanoparti-
cles (LBNs) encapsulating the SB 
system. These LBNs are chemically 
modulated to present synthetically 
reiterated MSC-targeting peptides 
on their surface [69]. Nanoparti-
cle-like protocells with SB encapsu-
lated inside can deliver the thera-
peutic gene into cancer cells, when 
folic acid is incorporated as a cancer 
cell-targeting motif [70]. Further-
more, special hepatocyte-targeted 
carriers, such as proteoliposomes 
containing galactose-terminated 
glycoproteins (e.g., the F protein 
of the Sendai virus) were demon-
strated to effectively deliver the SB 
cargo into hepatocytes [71]. In a 
different approach, cell type-specif-
ic gene targeting using hyaluronan- 
and asialoorosomucoid-coated 
 f FIGURE 7
Advancements in Sleeping Beauty transposon vectorization.
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Gene of interest
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Disabled transposase
binding sites
(1) Wildtype transposon   (2) Sandwich transposon
(i)
(ii) ITR ITR
Gene of interest
Illustration of the wild-type (i) and sandwich (ii) SB transposons. The sandwich 
transposon consists of two complete SB elements (ITRs) flanking the gene of interest in 
an inverted orientation. Because of the mutations (pentagon filled with wide downward 
diagonal lines) in the right ITRs (dark aqua blue arrow), only the full composite element 
can be mobilized. This arrangement of the sandwich SB transposon vector has enhanced 
capacity to efficiently transpose large cargos (>10kb).
CELL & GENE THERAPY INSIGHTS 
142 DOI: 10.18609/cgti.2017.014
nanocapsules harboring the SB sys-
tem were successfully used in vivo 
to direct genes to liver sinusoidal 
endothelial cells and hepatocytes, 
respectively [72]. Collectively, these 
studies imply that with the tar-
geting ligand modification, the 
nanoparticle-like carriers can be 
developed as efficient gene delivery 
and targeting gene vehicles, high-
lighting their therapeutic potential.
Apart from the non-viral strate-
gies, various SB-based viral hybrid 
technologies have been developed 
that can advantageously merge the 
excellent delivery properties of the 
viral vectors and the superior safe-
ty properties of the SB (Table 3 & 
Figure 8) (also reviewed in [41,63]). 
Currently, one of the most prom-
ising strategies is the in vivo gene 
transduction system based on a hy-
brid transposon/adenovirus vector 
[73] and hyperactive SB transposase 
(SB100X) [74]. This in vivo strategy 
is effective and safe, and performs 
without the requirement of ex vivo 
expansion and transduction of he-
matopoietic stem cells (HSCs) [75]. 
Eliminating bacterial  
sequences from the  
transposon vector
Non-viral delivery of large plasmid 
DNA molecules via electroporation 
is highly toxic to certain cell types, 
  f TABLE 3
List of various Sleeping Beauty–viral hybrid technologies.
Hybrid 
technology
Delivering 
vehicle
Integration 
machinery
Pack-
aging 
capacity
Advantages Ref.
Adeno/SB Recom-
binant 
adenovirus
SB10 >35 kb Transduce 
dividing and 
non-dividing 
cells, and 
are one of 
the most 
efficient 
vehicles for 
in vivo gene 
delivery
[98]
HCAdV/SB HCAdV HSB5 >36 kb Showed negligible 
toxicity in mice 
and canine model 
for hemophilia B
[110]
HCAdV/SB HCAdV  SB100X >36 kb Lowest immuno-
genicity and tox-
icity compared to 
early generation 
adenoviral vectors
[74]
AAV/SB Recombi-
nant AAV
SB100X >5 kb Stabilized transgene expression in 
combination with the high trans-
duction efficiencies of AAV
[99]
HSV-1 
amplicon/
SB
HSV-1 SB10; HSB5; 
SB12 
≤130 kb Efficient at delivering large trans-
genes to neurons specifically 
and provides stable long term 
expression
[100–
103]
Baculo/SB Baculovirus SB11 
SB100X 
38 kb Stable long term expression [104]
IDLV/SB IDLV SB10; SB11; 
HSB3; 
SB80X and 
SB100X
8 kb Un-biased random integration 
profile
[105]
Adeno: Adenovirus; Baculo: Baculovirus; HCAdV: High-capacity adenoviral vector; AAV: Adeno associated virus); IDLV: Integrase 
defective lenti virus; HSV-1: herpes simplex virus 1 amplicon.
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 f FIGURE 8
Delivery of the Sleeping Beauty transposon system into cells for cell & gene therapy applications.
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arrows) directly into the nucleus via nucleofection instead of plasmids. Using mRNA instead of DNA is beneficial in preventing genomic 
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ends (ITRs) resulting in excision and ultimately integrating into the chromosomal DNA of the genome. Stable genomic integration 
confers long-term expression of the gene of interest delivered by the transposon.
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including primary T cells. Reduc-
ing the size of the DNA, and using 
supercoil DNA proved to be advan-
tageous modifications in the deliv-
ery protocol [76,77]. Furthermore, 
the use of conventional plasmids 
as vectors that are propagated and 
isolated from bacteria raises a safety 
concern and a roadblock for broad 
clinical applications. In fact, the 
presence of bacterial backbone se-
quences on conventional plasmids 
such as antibiotic resistance gene 
and bacterial origin of replication 
has a number of negative conse-
quences (Figure 9i). First, bacterial 
sequences are recognized and trig-
ger gene silencing [78,79]. Second, 
 f FIGURE 9
Schematic overview of alternative vector selection approaches according to the size and transfection 
efficiency.
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Development of novel transposon vectors that are free of bacterial components for clinical applications. Structural components of 
conventional (i), pFAR (ii) and minicircle (MC; iii) plasmids are illustrated. Typical conventional plasmid (i) contains a bacterial propagation 
unit and an eukaryotic expression unit. Bacterial propagation components like origin of replication (ori) and antibiotic resistance gene 
are not desirable for clinical applications. Efforts in eliminating the bacterial components resulted in the development of pFAR and MC 
vectors. pFAR vectors are free of antibiotic resistance gene, replaced by a suppressor t-RNA gene (Sup t-RNA) for bacterial selection and 
propagation (see also text). pFAR vectors still have bacterial origin of replication (ori). MC represents vectors that contain no bacterial 
components. MCs are generated by an intramolecular recombination (Rec). Because of their reduced size and sequences of bacterial 
origin pFAR and MC miniplamids enable more efficient transfections and offer sustained expression compared to conventional plasmid 
vectors. Components of the conventional (i), pFAR (ii) and minicircle (MC; iii) plasmids are not proportional to the size and are not at 
scale. ITR-inverted terminal repeat; Prom-promoter; PA-polyadenylation.
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expression of antibiotic resistance 
genes can also induce undesired 
immune responses [79]. Further-
more, transmission of antibiotic 
resistance genes to the cells or the 
microbiota of the patient via hor-
izontal gene transfer generates po-
tential risks. For the above safety 
considerations regulatory agencies 
recommend avoiding the use of an-
tibiotic resistance markers.
The need to eliminate redundant 
bacterial backbone sequences moti-
vated researcher’s to consider new 
approaches that reduces the size 
and bacterial sequence content of 
the plasmids. These efforts resulted 
in the development of plasmid free 
of antibiotic resistance (pFAR; see 
below and Figure 9ii) and minicircle 
(MC) vectors (Figure 9iii).
pFAR vectors are produced un-
der selection pressure in a genetical-
ly modified E. coli, which contains 
an amber mutation in the thymi-
dylate synthase gene. Introduction 
of pFAR plasmids having the sup-
pressor transfer RNA gene (Sup 
t-RNA) into the mutant E. coli can 
restore normal growth, providing a 
selection pressure for the mainte-
nance of pFAR miniplasmids. The 
pFAR miniplasmids are much more 
efficient (in transfection as well 
as expression in vitro and in vivo) 
compared to the conventional plas-
mids (Figure 9ii) [80]. Importantly, 
the pFAR and SB technologies were 
successfully combined [Johnen S, In 
press], and would be used in the 
clinical trial to treat AMD. 
Minicircle DNA vectors repre-
sent small and supercoiled mole-
cules that are devoid of any bacte-
rial sequences, and contain almost 
exclusively the GOI. They are pro-
duced by the inclusion of site-spe-
cific intramolecular recombina-
tion motifs between the GOI and 
bacterial backbone in the parental 
plasmid. SB transposon and trans-
posase minicircle constructs have 
been examined and optimized for 
safety and efficacy in various cell 
types [77], including primary T cells 
[76]. A minicircles-based SB system 
has been also used for efficient ger-
mline transgenesis [81]. Minicircle 
vectors seem to improve the trans-
fection efficiency and transgene ex-
pression, while decreasing the tox-
icity associated with DNA delivery 
(Figure 9iii). 
Collectively, miniplasmid vectors 
could be optimized for a variety of 
cell types, might meet future regula-
tory requirements for gene therapy 
and vaccine products, and set a new 
standard in advanced cellular and 
gene therapy. 
Selection strategies for 
engineered cells expressing 
the gene of interest
Certain clinical applications require 
a large number of engineered cells. 
Thus, high efficacy of delivery and 
the frequency of therapeutic gene 
integration are crucial. In addition, 
it might be necessary to further 
enrich engineered cell cultures by 
using selective culturing protocols. 
Ideally, the selection period should 
be short. The following selection 
strategies have been tested for se-
lecting genetically modified cells 
using the SB system.
In a cancer immunotherapy ap-
plication, T cells are genetically 
modified by nucleofecting the SB 
system to express chimeric antigen 
receptor (CAR) that redirects spec-
ificity towards tumors. For exam-
ple, CD19-specific CAR+ T cells 
could be selectively expanded on 
K562-derived artificial presenting 
cells (aAPC) co-expressing human 
CD19 and in the presence of an 
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array of co-stimulatory molecules. 
Co-expression of CD19 serves to 
specifically propagate the genetically 
modified T cells, leaving those cells 
that did not integrate the transposon 
to die from neglect. This method of 
expansion strategy can efficiently 
overcome the toxicity of nucleofec-
tion and yield sufficient numbers 
of CD19- specific CAR+ T cells for 
clinical applications [82,83].
In an alternative protocol, ad-
ministration of irradiated PBMCs 
was used to overcome cell death 
following SB-mediated gene trans-
fer of CAR-modified cytokine-in-
duced killer cells (CIKs). This clin-
ical-grade protocol enables both 
robust gene transfer and efficient 
T cell expansion [84].
In addition, the SB transposon 
system has also been used for multi-
plexed gene transfer in conjugation 
with methotrexate selection. The 
strategy allows stable expression of 
up to three different transgenes in 
human CD4+ T cells [85].
Alternatively to cytotoxic drugs, a 
chemically responsive amplification 
mechanism can be used for selecting 
the engineered cells. A nearly pure 
population of stably transduced cells 
can be generated by non-viral deliv-
ery of desired transgenes through a 
combination of SB transposon-me-
diated integration and selective 
amplification using a chemically 
induced dimerizer (CID) [86]. This 
positive selection strategy is respon-
sive to a small molecule trigger. Us-
ing this fast and efficient selection 
strategy, engineered cell populations 
with >98% purity could be obtained 
within 1 week. Dimerizer-induced 
cell growth could provide cost and 
reproducibility advantages to natu-
ral ligand stimulation in ex vivo cell 
culture, and could be used to control 
engineered cell behavior in vivo.
A ‘traceless selection system’ can 
efficiently select for engineered 
cells, and can be also used to select 
against cells that retain expression 
of the transposase gene. In this ap-
proach, the transposase is expressed 
together with a tractable fluorescent 
reporter. The strategy is based on 
the observation that upon co-trans-
fection of both the transposase and 
transposon constructs, the presence 
of the transposase also reports on 
successful transposition events with 
high frequency. This concept could 
be used to produce highly enriched, 
auxiliary gene-free, cell products 
[87] that meet important safety 
requirements. 
Regulation of the transgene 
expression 
Transcriptional regulation could 
control the timing and dose of the 
expression of the therapeutic gene. 
In principle, the SB vector, possess-
ing negligible enhancer/promoter 
activity on its own [26,88] can be 
easily adopted for transcriptional 
regulation. For regulated transgene 
expression ‘all-in-one’ TET SB vec-
tors display a relatively low signal-
to-noise ratio, resulting in regulato-
ry windows of around 25,000-fold 
[89]. For safety concerns it is desir-
able to secure even elimination of 
the therapeutic gene. In conjunc-
tion with the SB system, thymidine 
kinase (TK) can be used for condi-
tional ablation of the therapeutic 
construct [90]. 
Supporting protocols to 
monitor the safety and 
efficacy 
 f  Following SB-mediated integr-
ation determining the copy 
number of the therapeutic gene 
is usually performed by PCR-
based assays [13,91]. At very 
limited amounts of DNA droplet 
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digital PCR can be successful to 
precisely determine the number 
of integrated vector copies;
 f  A high throughput integration 
site analysis belongs to the 
routinely performed safety 
studies. These analyses recover 
SB integration sites from the 
treated cells, and compare them 
to a computationally generated 
random genomic control [75]. 
SB exhibits a close-to-random 
integration profile with a small 
bias at repetitive elements [31]. 
The integration sites can be 
further investigated in various 
categories (e.g., library of safe 
harbor genomic sites, exons, 
regulatory regions, etc.) [35];
 f A recently reported whole-
body non-invasive imaging 
provides a method to examine 
long-term bio-distribution and 
persistence of the engineered 
cells. In this technology, 
bioluminescent imaging is used 
to monitor the signal emitted 
by firefly luciferase from the 
SB vector in vivo. The positron 
emission tomography (PET) is 
applied following injection of 
2’-deoxy-2’-[18F]fluoro-5-ethyl-
1-β-D-arabinofuranosyl-uracil 
([18F]FEAU). Besides, monitoring 
safety, such a non-invasive 
imaging approach could be useful 
for assessing the efficacy of the 
therapeutic strategy [90]. 
Clinical evaluation of 
SB transposon system/
technology 
Assignees for SB patent applications 
are associated with two leading or-
ganizations (University of Minne-
sota and the Max Delbrück Center 
for Molecular Medicine (MDC)). 
As discussed above (Figures 4–6), SB 
transposon technology applications 
span the cell and gene therapy in-
dustry market that has experienced 
rapid growth in the last few years 
(Table 4 & Figure 10). The ‘simple’ 
search (with the term ‘sleeping 
beauty transposon’) using the pat-
entscope search tool [92] of world 
intellectual property organization 
  f TABLE 4
Industry interests in using Sleeping Beauty transposon technologies.
Company Application Area
Discovery Genomics, Inc. 
(DGI)
Gene therapy Diseases of blood
B-MoGen Biotechnologies Inc. Gene delivery and gene editing Providing tools and custom 
services
Intrexon Corp. Gene therapy Cancer immunotherapy
Ziopharm Onclogy Gene therapy Cancer immunotherapy
Merck Gene therapy Cancer immunotherapy
Formula Pharmaceuticals, Inc. Gene therapy Cancer immunotherapy
Immusoft Corporation Gene therapy Rare diseases
NsGene A/S Gene therapy Neurological diseases (like 
Alzheimer’s disease, etc.)
Aldevron, LLC Custom development and manu-
facturing services
Providing tools and custom 
services
Harborgen Biotechnologies, 
Inc.
DNA and related testing prod-
ucts development of precision 
medicine
Providing tools and custom 
services
Neuromics, Inc. Bio-reagents company Providing tools 
Plasmid factory Providing reagents and custom services
Pharmead Providing reagents and custom services
The data presented in the table is obtained either based on the available information or by searching various online sources as of March 
2017. Note that companies that have confidentially licensed the SB transposon technology are not listed in the presented table.
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 f FIGURE 10
Patent landscape and partnership relations of academic institutions and industrial partners involving the 
Sleeping Beauty transposon system as of March 2017.
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Percentage share of the International Patent Classification (IPC). Majority of the patents involving the SB has been submitted in the 
category-C12N (inventions concerning microorganisms, enzymes; compositions thereof mutation or genetic engineering); A61K 
(inventions concerning pharmaceutical field-preparations for medical purposes); A01K (inventions concerning animal husbandry); 
A01N; C07H and G01N. Academic-industrial partnership can bridge the ‘gap’ between research done in academia and its translation into 
marketable products. Recently, the University of Minnesota’s patented SB-based gene delivery technology (SB11 and pT2) pooled with 
patents of cancer therapies practiced by the University of Texas’ MD Anderson Cancer Center. This bi-institutional technology sparked a 
landmark of $100 million licensing deal with biotech company Intrexon Corp. and pharmaceutical company Ziopharm Oncology [106]. 2 
months later, the drugmaker Merck offered to pay Intrexon and Ziopharm nearly $1 billion, plus royalties for an upstart CAR T cancer drug 
development project [97]. Arrows indicate the license agreement (s) between the parties. Normal line indicates a mutual collaboration 
or industry-academic partnership. DGI: Discovery Genomics, Inc.; FORM: Formula Pharmaceuticals, Inc.; IMS: Immusoft Corporation; 
MDC: Max Delbrück Center for Molecular Medicine in the Helmholtz Association; NCI: National Cancer Institute; UoM: University of 
Minnesota; UoT MD A: University of Texas’ MD Anderson Cancer Center; XON:  Intrexon Corporation; ZIOP: Ziopharm Oncology.
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(WIPO) resulted in 19 patent ap-
plications or documents, involving 
SB. Majority of the patent applica-
tions are from the USA and Europe. 
Most of the SB patents are in the 
category C12N (inventions con-
cerning microorganisms, enzymes; 
compositions thereof mutation 
or genetic engineering), followed 
by A61K (inventions concerning 
pharmaceutical field-preparations 
for medical purposes) and A01K 
(inventions concerning animal hus-
bandry) (Figure 10A). 
There are currently ten ongoing 
clinical trials in USA employing SB 
(Table 5). These trials use the SB11/
pT2 version of the transposon sys-
tem aiming to treat B-cell malig-
nancies and metastatic breast can-
cer. In addition, the hyperactive 
SB100X-generated stable cell line 
in conjunction with Encapsulated 
Cell BiodeliveryTM was trialed to 
treat AD patients (ClinicalTrials.gov 
identifier: NCT01163825) (Table 5). 
Another clinical trial is planned to 
launch in 2017, which would em-
ploy SB100X and pFAR technologies 
to treat AMD (TargetAMD [93]).
Because of the significant com-
plexities associated with cell engi-
neering and therapy, partnerships 
tend to link different players, includ-
ing academic research institutions 
and the biotech/pharma industries 
(Figure 10B). In one example, Uni-
versity of Minnesota has combined 
its patented SB-based gene delivery 
technology (SB11 and pT2) with 
intellectual properties of cancer 
therapies practiced by the Universi-
ty of Texas’ MD Anderson Cancer 
Center. This joint deal was meant to 
create the first-of-its kind non-viral 
immunotherapy treatment to sup-
port the patient’s immune system 
to fight against cancer. In an at-
tempt to develop and evaluate the 
potential of immunotherapy to treat 
solid tumors, Intrexon and Zio-
pharm announced a Cooperative 
Research and Development Agree-
ment (CRADA) with the National 
Cancer Institute (NCI). This join 
corporation will use T-cell receptors 
(TCRs) expressed by the non-viral 
SB system [94]. Recently, Immu-
soft acquired an exclusive access to 
use the SB transposon technology 
through acquisition of Discovery 
Genomics, Inc., which will be used 
for the development of autologous 
cell therapy products for treating a 
variety of diseases. Immusoft’s pro-
prietary Immune System Program-
ming (ISP™) technology would 
be used to program patients own 
B cells to generate miniature drug 
factories in the body. The Immusoft 
technology platform would use the 
SB transposon system for inserting 
genes encoding the correct human 
homolog of a missing or defective 
protein(s) to boost the patient’s own 
immune cells. Certain companies 
are providing reagents and custom 
services of SB transposon technolo-
gy for research and clinical applica-
tions (Table 4).
In an attempt to replicate the 
success of SB in therapeutic appli-
cations, MDC has established an 
exclusive licensing agreement and 
strategic collaboration with For-
mula Pharmaceuticals, Inc. for the 
development of Cytokine Induced 
Killer (C.I.K.) cell-based Chimeric 
Antigen Receptor (CAR) immuno-
therapies. The collaboration plat-
form is partially sponsored by the 
Helmholtz Association (MD-Cell, 
Innovation Lab), and would use 
MDC’s proprietaries, the hyperac-
tive SB100X transposase and pT4 
transposon, the optimized compo-
nents of the SB transposon-based 
gene transfer system [95]. 
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TRANSLATIONAL INSIGHT 
Despite periods of serious stag-
nation over the past few decades, 
the future of cell and gene therapy 
seems to be brighter. The turn-
around began about a decade ago, 
and has been on an exponential 
trajectory by overcoming the ear-
ly issues. Besides using tradition-
al viral vectors, recent years have 
seen major breakthroughs in ge-
nome engineering systems, such as 
transposon-mediated gene deliv-
ery and CRISPR/Cas9-mediated 
genome editing tools. As discussed 
above, SB appears to be a relative 
low risk and efficient gene delivery 
vector, and represents a safer alter-
native to integrating viral vectors. 
In parallel, rapid development oc-
curred also in the CRISPR/Cas9 
technology that can be developed 
for genome editing. These tech-
nologies became available in many 
species and have revolutionized 
genome engineering. These two 
approaches appear to have distinct 
features, and might occupy com-
plementary niches in therapeutic 
applications. For example, due 
to its ability to specifically target 
sequences, the CRISPR/Cas9 sys-
tem appears to be ideal for knock-
ing out strategies. Currently it is 
tested in many pre-clinical stud-
ies, and could be on its way to-
wards clinical applications in the 
near future. By contrast, although 
 f FIGURE 11
Milestones and developments in Sleeping Beauty transposon technology for various therapeutic applica-
tions as of March 2017.
McClintock was awarded the Nobel Prize for the discovery of transposons
Resurrection and establishment of SB transposon system
Integration profile of SB was found to be fairly random
First proof-of-concept and prototype for targeted transposition
First clinical trial in USA using SB for B-cell malignancies
Development of the hyperactive version of SB called SB100X
SB-based gene therapy to treat Alzheimer’s disease
SB-based gene therapy to treat AMD
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proof-of-concept studies exist to 
demonstrate that SB can be tar-
geted to predetermined genomic 
loci [23,24], the current SB system 
is not suitable for flexible and ef-
ficient sequence-specific genome 
targeting. Nevertheless, among 
integrating gene delivery vectors 
the SB system has the highest 
chance of landing in a genom-
ic safe harbor [35]. On the other 
side, today’s CRISPR/Cas9 strat-
egies to manipulate large genomic 
regions (knocking in) face clear 
limitations for clinical translation. 
The current knock-in protocols 
are tightly dependent on homolo-
gous recombination of the cellular 
DNA repair machinery that has 
low activity in many clinically rel-
evant cell types. Thus, compared 
to CRISPR/Cas9, the SB system 
is more suitable for applications 
that require ‘gene insertion’ (es-
pecially large genes). Regarding 
safety, the SB-mediated transgene 
integration is highly regulated and 
precise, and does not generate un-
specific double stranded breaks in 
the genome (off target). 
In addition to ex vivo applica-
tions, an important milestone in 
the SB technology is in vivo deliv-
ery. This gene transduction system 
is based on a hybrid transposon/
adenovirus vector and the hyperac-
tive SB transposase (SB100X) [74]. 
This in vivo strategy is effective and 
safe in hematopoietic stem cells 
(HSCs), and performs without 
the requirement of ex vivo expan-
sion and transduction [75,96]. This 
system may overcome some of the 
current difficulties associated with 
cell collection and manufacturing, 
and provide technical advances for 
gene therapy.
Collectively, the significant 
efforts invested in developing 
genome-engineering tools begin 
to pay dividends, as we witness an 
increasing interest in using them in 
various applications, including cell 
and gene therapy. The SB-mediat-
ed gene transfer is currently being 
evaluated in 12 clinical trials (Figure 
11). In the coming years, the num-
ber of trials using genome-engi-
neering systems is forecasted to in-
crease, attracting further investment 
from the pharma as well as biotech 
companies.
ACKNOWLEDGEMENTS
We would like to acknowledge Dr Zoltan 
Ivics for his useful comments. ZI is sup-
ported by ERC Advanced Grant ERC-
2011-AdG 294742-TRANSPOSOstress.
FINANCIAL & COMPETING  
INTERESTS DISCLOSURE
The authors have no relevant  financial 
involvement with an organization 
or entity with a financial interest in 
or financial conflict with the subject 
matter or materials discussed in the 
manuscript. SN and ZI are employees 
of the MDC. ZI has several patent 
applications on Sleeping Beauty. 
No writing assistance was utilized in the 
production of this manuscript.
This work is licensed under 
a Creative Commons Attri-
bution – NonCommercial – NoDerivatives 4.0 
International License
CELL & GENE THERAPY INSIGHTS 
154 DOI: 10.18609/cgti.2017.014
REFERENCES
1. Vectors used in gene therapy clinical 
trials: http://www.abedia.com/wiley/
vectors.php
2. Thomas CE, Ehrhardt A, Kay MA. 
Progress and problems with the use 
of viral vectors for gene therapy. Nat. 
Rev. Genet. 2003; 4: 346–58.
3. Hartman ZC, Appledorn DM, Amal-
fitano A. Adenovirus vector induced 
innate immune responses: impact 
upon efficacy and toxicity in gene 
therapy and vaccine applications. Vi-
rus Res. 2008; 132: 1–14.
4. Roe T, Reynolds TC, Yu G, Brown 
PO. Integration of murine leukemia 
virus DNA depends on mitosis. Embo 
J. 1993; 12: 2099–108.
5. Lewinski MK, Yamashita M, Emer-
man M et al. Retroviral DNA integra-
tion: viral and cellular determinants 
of target-site selection. PLoS Pathog. 
2006; 2: e60.
6. Hacein-Bey-Abina S, Von Kalle C, 
Schmidt M et al. LMO2-associated 
clonal T cell proliferation in two pa-
tients after gene therapy for SCID-X1. 
Science 2003; 302: 415–9.
7. Baum C, von Kalle C, Staal FJ, Li Z 
et al. Chance or necessity? Insertion-
al mutagenesis in gene therapy and 
its consequences. Mol. Ther. 2004; 9: 
5–13.
8. Ivics Z, Hackett PB, Plasterk RH, 
Izsvak Z. Molecular reconstruction 
of Sleeping Beauty, a Tc1-like trans-
poson from fish, and its transposi-
tion in human cells. Cell 1997; 91: 
501–10.
9. Izsvak Z, Ivics Z, Plasterk RH. Sleep-
ing Beauty, a wide host-range trans-
poson vector for genetic transforma-
tion in vertebrates. J. Mol. Biol. 2000; 
302: 93-102.
10. Wilber A, Wangensteen KJ, Chen 
Y et al. Messenger RNA as a source 
of transposase for sleeping beauty 
transposon-mediated correction of 
hereditary tyrosinemia type I. Mol. 
Ther. 2007; 15: 1280–7.
11. Cui Z, Geurts AM, Liu G et al. Struc-
ture-function analysis of the inverted 
terminal repeats of the sleeping beau-
ty transposon. J. Mol. Biol. 2002; 318: 
1221–35.
12. Wang Y, Pryputniewicz-Dobrinska 
D, Nagy EE et al. Regulated complex 
assembly safeguards the fidelity of 
Sleeping Beauty transposition. Nucleic 
Acids Res. 2017 45: 311–326.
13. Kowarz E, Loscher D, Marschalek 
R. Optimized Sleeping Beauty trans-
posons rapidly generate stable trans-
genic cell lines. Biotechnol. J. 2015; 
10: 647–53.
14. Mates L, Chuah MK, Belay E et al. 
Molecular evolution of a novel hy-
peractive Sleeping Beauty transposase 
enables robust stable gene transfer 
in vertebrates. Nat. Genet. 2009; 41: 
753–61. 
15. Izsvak Z, Khare D, Behlke J et al. In-
volvement of a bifunctional, paired-
like DNA-binding domain and a 
transpositional enhancer in Sleeping 
Beauty transposition. J. Biol. Chem. 
2002; 277: 34581–8.
16. Izsvak Z, Stuwe EE, Fiedler D et al. 
Healing the wounds inflicted by 
sleeping beauty transposition by dou-
ble-strand break repair in mammali-
an somatic cells. Mol Cell. 2004; 13: 
279–90.
17. Wang Y, Wang J, Devaraj A et al. 
Suicidal autointegration of sleeping 
beauty and piggyBac transposons in 
eukaryotic cells. PLoS Genet. 2014; 
10: e1004103.
18. Luo G, Ivics Z, Izsvak Z, Bradley A. 
Chromosomal transposition of a Tc1/
mariner-like element in mouse em-
bryonic stem cells. Proc. Natl Acad. 
Sci. USA 1998; 95: 10769–73.
19. Yant SR, Kay MA. Nonhomolo-
gous-end-joining factors regulate 
DNA repair fidelity during Sleep-
ing Beauty element transposition 
in mammalian cells. Mol. Cell Biol. 
2003; 23: 8505–18.
20. Vigdal TJ, Kaufman CD, Izsvak Z et 
al. Common physical properties of 
DNA affecting target site selection of 
sleeping beauty and other Tc1/mar-
iner transposable elements. J. Mol. 
Biol. 2002; 323: 441–52.
21. Ivics Z, Katzer A, Stuwe EE et al. Tar-
geted Sleeping Beauty transposition 
in human cells. Mol. Ther. 2007; 15: 
1137–44.
22. Yant SR, Huang Y, Akache B, Kay 
MA. Site-directed transposon integra-
tion in human cells. Nucleic Acids Res. 
2007; 35: e50.
23. Ammar I, Gogol-Doring A, Miskey 
C et al. Retargeting transposon in-
sertions by the adeno-associated virus 
Rep protein. Nucleic Acids Res. 2012; 
40: 6693–712.
24. Voigt K, Gogol-Doring A, Miskey 
C et al. Retargeting sleeping beauty 
transposon insertions by engineered 
zinc finger DNA-binding domains. 
Mol. Ther. 2012; 20: 1852–62.
25. Zayed H, Izsvak Z, Khare D et al. The 
DNA-bending protein HMGB1 is a 
cellular cofactor of Sleeping Beauty 
transposition. Nucleic Acids Res. 2003; 
31: 2313–22.
26. Walisko O, Schorn A, Rolfs F et al. 
Transcriptional activities of the Sleep-
ing Beauty transposon and shielding 
its genetic cargo with insulators. Mol. 
Ther. 2008; 16: 359–69.
27. Walisko O, Izsvak Z, Szabo K et al. 
Sleeping Beauty transposase modu-
lates cell-cycle progression through in-
teraction with Miz-1. Proc. Natl Acad. 
Sci. USA 2006; 103: 4062–7.
EXPERT INSIGHT 
155Cell & Gene Therapy Insights - ISSN: 2059-7800 
28. Yusa K, Takeda J, Horie K. Enhance-
ment of Sleeping Beauty transposition 
by CpG methylation: possible role of 
heterochromatin formation. Mol. Cell 
Biol. 2004; 24: 4004–18.
29. Huang X, Wilber AC, Bao L et al. 
Stable gene transfer and expression in 
human primary T cells by the Sleep-
ing Beauty transposon system. Blood 
2006; 107: 483–91.
30. Rostovskaya M, Fu J, Obst M et al. 
Transposon-mediated BAC transgen-
esis in human ES cells. Nucleic Acids 
Res. 2012; 40: e150.
31. Yant SR, Wu X, Huang Y et al. 
High-resolution genome-wide map-
ping of transposon integration in 
mammals. Mol. Cell Biol. 2005; 25: 
2085–94.
32. Liu G, Geurts AM, Yae K et al. Tar-
get-site preferences of Sleeping Beauty 
transposons. J. Mol. Biol. 2005; 346: 
161–73.
33. Geurts AM, Hackett CS, Bell JB et 
al. Structure-based prediction of in-
sertion-site preferences of transposons 
into chromosomes. Nucleic Acids Res. 
2006; 34: 2803–11.
34. Huang X, Guo H, Tammana S et 
al. Gene transfer efficiency and ge-
nome-wide integration profiling of 
Sleeping Beauty, Tol2, and piggyBac 
transposons in human primary T 
cells. Mol. Ther. 2010; 18: 1803–13.
35. Gogol-Döring A, Ammar I, Gupta 
S et al. Genome-wide Profiling Re-
veals Remarkable Parallels Between 
Insertion Site Selection Properties of 
the MLV Retrovirus and the piggy-
Bac Transposon in Primary Human 
CD4(+) T Cells. Mol. Ther. 2016; 24: 
592–606.
36. Henssen AG, Henaff E, Jiang E et al. 
Genomic DNA transposition induced 
by human PGBD5. Elife  2015; 4.
37. Ivics Z. Endogenous Transposase 
Source in Human Cells Mobilizes 
piggyBac Transposons. Mol. Ther. 
2016; 24: 851–4.
38. Ivics Z, Izsvak Z. The expanding uni-
verse of transposon technologies for 
gene and cell engineering. Mob. DNA 
2010; 1: 25.
39. Wachter K, Kowarz E, Marschalek 
R. Functional characterisation of dif-
ferent MLL fusion proteins by using 
inducible Sleeping Beauty vectors. 
Cancer Lett.  2014; 352: 196–202.
40. Ammar I, Izsvak Z, Ivics Z. The Sleep-
ing Beauty transposon toolbox. Meth-
ods Mol. Biol. 2012; 859: 229–40.
41. Narayanavari SA, Chilkunda SS, Iv-
ics Z. Sleeping Beauty transposition: 
from biology to applications. Crit. 
Rev. Biochem. Mol. Biol. 2016; 1–27.
42. Katter K, Geurts AM, Hoffmann O et 
al. Transposon-mediated transgenesis, 
transgenic rescue, and tissue-specific 
gene expression in rodents and rab-
bits. FASEB J. 2013; 27: 930–41.
43. Alessio AP, Fili AE, Garrels W et al. 
Establishment of cell-based trans-
poson-mediated transgenesis in cattle. 
Theriogenology 2016; 85: 1297–1311 
e2.
44. Davis RP, Nemes C, Varga E et al. 
Generation of induced pluripotent 
stem cells from human foetal fibro-
blasts using the Sleeping Beauty trans-
poson gene delivery system. Differen-
tiation 2013; 86: 30–7.
45. Grabundzija I, Wang J, Sebe A et al. 
Sleeping Beauty transposon-based sys-
tem for cellular reprogramming and 
targeted gene insertion in induced 
pluripotent stem cells. Nucleic Acids 
Res. 2013; 41: 1829–1847.
46. Kaji K, Norrby K, Paca A et al. Vi-
rus-free induction of pluripotency 
and subsequent excision of repro-
gramming factors. Nature 2009; 458: 
771–5.
47. Fatima A, Ivanyuk D, Herms S et 
al. Generation of human induced 
pluripotent stem cell line from a pa-
tient with a long QT syndrome type 
2. Stem Cell Res. 2016; 16: 304–7.
48. Kues WA, Herrmann D, Barg-Kues B 
et al. Derivation and characterization 
of sleeping beauty transposon-me-
diated porcine induced pluripotent 
stem cells. Stem Cells Dev. 2013; 22: 
124–35.
49. Muenthaisong S, Ujhelly O, Polgar 
Z et al. Generation of mouse induced 
pluripotent stem cells from different 
genetic backgrounds using Sleeping 
beauty transposon mediated gene 
transfer. Exp. Cell Res. 2012; 318: 
2482–9.
50. Talluri TR, Kumar D, Glage S et al. 
Derivation and characterization of bo-
vine induced pluripotent stem cells by 
transposon-mediated reprogramming. 
Cell Reprogram 2015; 17: 131–40.
51. Wang J, Xie G, Singh M et al. Pri-
mate-specific endogenous retrovi-
rus-driven transcription defines na-
ive-like stem cells. Nature 2014; 516: 
405–9.
52. Wang J, Singh M, Sun C et al. Iso-
lation and cultivation of naive-like 
human pluripotent stem cells based 
on HERVH expression. Nat. Protoc. 
2016; 11: 327–46.
53. Keng VW, Yae K, Hayakawa T et al. 
Region-specific saturation germline 
mutagenesis in mice using the Sleep-
ing Beauty transposon system. Nat. 
Methods 2005; 2: 763–9.
54. Izsvak Z, Ivics Z. Sleeping Beauty hits 
them all: transposon-mediated satura-
tion mutagenesis in the mouse germ-
line. Nat. Methods 2005; 2: 735–6.
55. Kokubu C, Horie K, Abe K et al. A 
transposon-based chromosomal en-
gineering method to survey a large 
cis-regulatory landscape in mice. Nat. 
Genet. 2009; 41: 946–52.
56. Copeland NG, Jenkins NA. Har-
nessing transposons for cancer gene 
CELL & GENE THERAPY INSIGHTS 
156 DOI: 10.18609/cgti.2017.014
discovery. Nat. Rev. Cancer 2010; 10: 
696–706.
57. Moriarity BS, Largaespada DA. Sleep-
ing Beauty transposon insertional mu-
tagenesis based mouse models for can-
cer gene discovery. Curr. Opin. Genet. 
Dev. 2015; 30: 66–72.
58. Ruf S, Symmons O, Uslu VV et al. 
Large-scale analysis of the regulato-
ry architecture of the mouse genome 
with a transposon-associated sensor. 
Nat. Genet. 2011; 43: 379–86.
59. Pindyurin AV, de Jong J, Akhtar W. 
TRIP through the chromatin: a high 
throughput exploration of enhancer 
regulatory landscapes. Genomics 
2015; 106: 171–7.
60. Izsvak Z, Hackett PB, Cooper LJ. 
Translating Sleeping Beauty transpo-
sition into cellular therapies: victories 
and challenges. Bioessays 2010; 32: 
756–67.
61. Hackett PB, Largaespada DA, Switzer 
KC. Evaluating risks of insertional 
mutagenesis by DNA transposons in 
gene therapy. Transl. Res. 2013; 161: 
265–83.
62. Swierczek M, Izsvak Z, Ivics Z. The 
Sleeping Beauty transposon system 
for clinical applications. Expert Opin. 
Biol. Ther. 2012; 12: 139–53.
63. Boehme P, Doerner J, Solanki M et al. 
The sleeping beauty transposon vector 
system for treatment of rare genetic 
diseases: an unrealized hope? Curr. 
Gene Ther. 2015; 15: 255–65.
64. Jin Z, Maiti S, Huls H, Singh H et 
al. The hyperactive Sleeping Beauty 
transposase SB100X improves the ge-
netic modification of T cells to express 
a chimeric antigen receptor. Gene 
Ther. 2011; 18: 849–56.
65. Petrov DA, Schutzman JL, Hartl DL, 
Lozovskaya ER. Diverse transposable 
elements are mobilized in hybrid dys-
genesis in Drosophila virilis. Proc. Natl 
Acad. Sci. USA 1995; 92: 8050–4.
66. Zayed H, Izsvak Z, Walisko O, Ivics 
Z. Development of hyperactive sleep-
ing beauty transposon vectors by mu-
tational analysis. Mol. Ther. 2004; 9: 
292–304.
67. Turchiano G, Latella MC, Go-
gol-Doring A et al. Genomic analysis 
of Sleeping Beauty transposon inte-
gration in human somatic cells. PLoS 
One 9: 2014; e112712.
68. Sharma N, Hollensen AK, Bak RO et 
al. The impact of cHS4 insulators on 
DNA transposon vector mobilization 
and silencing in retinal pigment epi-
thelium cells. PLoS One 7: e48421.
69. Wang DD, Yang M, Zhu Y, Mao C. 
Reiterated Targeting Peptides on the 
Nanoparticle Surface Significantly 
Promote Targeted Vascular Endothe-
lial Growth Factor Gene Delivery to 
Stem Cells. Biomacromolecules 2015; 
16: 3897–903.
70. Ma K, Fu D, Yu D et al. Targeted 
delivery of in situ PCR-amplified 
Sleeping Beauty transposon genes to 
cancer cells with lipid-based nanopar-
ticle-like protocells. Biomaterials 
2017; 121: 55–63.
71. Wang X, Mani P, Sarkar DP et al. 
Ex vivo gene transfer into hepato-
cytes. Methods Mol. Biol. 2009; 481: 
117–40.
72. Kren BT, Unger GM, Sjeklocha L et 
al. Nanocapsule-delivered Sleeping 
Beauty mediates therapeutic Factor 
VIII expression in liver sinusoidal en-
dothelial cells of hemophilia A mice. 
J. Clin. Invest. 2009; 119: 2086–99.
73. Yant SR, Ehrhardt A, Mikkelsen JG et 
al. Transposition from a gutless ade-
no-transposon vector stabilizes trans-
gene expression in vivo. Nat. Biotech-
nol. 2002; 20: 999–1005.
74. Boehme P, Zhang W, Solanki M et al. 
A High-Capacity Adenoviral Hybrid 
Vector System Utilizing the Hyper-
active Sleeping Beauty Transposase 
SB100X for Enhanced Integration. 
Mol. Ther. Nucleic Acids 2016; 5: e337.
75. Richter M, Saydaminova K, Yumul R 
et al. In vivo transduction of primitive 
hematopoietic stem cells after mobi-
lization and intravenous injection of 
integrating adenovirus vectors. Blood 
2016; 128: 2206–17.
76. Monjezi R, Miskey C, Gogishvili T et 
al. Enhanced CAR T-cell engineering 
using non-viral Sleeping Beauty trans-
position from minicircle vectors. Leu-
kemia 2017; 31: 186–194.
77. Sharma N, Cai Y, Bak RO et al. Ef-
ficient sleeping beauty DNA trans-
position from DNA minicircles. Mol. 
Ther. Nucleic Acids 2013; 2: e74.
78. Simcikova M, Prather KL, Prazeres 
DM, Monteiro GA. Towards effec-
tive non-viral gene delivery vector. 
Biotechnol. Genet. Eng. Rev. 2015; 31: 
82–107.
79. Tolmachov OE,. Building mosaics 
of therapeutic plasmid gene vectors. 
Curr. Gene Ther. 2011; 11: 466–78.
80. Marie C, Vandermeulen G, Quiviger 
M et al. pFARs, plasmids free of an-
tibiotic resistance markers, display 
high-level transgene expression in 
muscle, skin and tumour cells. J. Gene 
Med. 2010; 12: 323–32.
81. Garrels W, Talluri TR, Ziegler M et 
al. Cytoplasmic injection of murine 
zygotes with Sleeping Beauty trans-
poson plasmids and minicircles results 
in the efficient generation of germline 
transgenic mice. Biotechnol. J. 2016; 
11: 178–84.
82. Singh H, Figliola MJ, Dawson MJ et 
al. Reprogramming CD19-specific T 
cells with IL-21 signaling can improve 
adoptive immunotherapy of B-lineage 
malignancies. Cancer Res. 2011; 71: 
3516–27.
83. Singh H, Manuri PR, Olivares S et al. 
Redirecting specificity of T-cell popu-
lations for CD19 using the Sleeping 
EXPERT INSIGHT 
157Cell & Gene Therapy Insights - ISSN: 2059-7800 
Beauty system. Cancer Res. 2008; 68: 
2961–71.
84. Magnani CF, Turazzi N, Benedicen-
ti F et al. Immunotherapy of acute 
leukemia by chimeric antigen re-
ceptor-modified lymphocytes using 
an improved Sleeping Beauty trans-
poson platform. Oncotarget 2016; 7: 
51581–97.
85. Kacherovsky N, Liu GW, Jensen MC, 
Pun SH. Multiplexed gene transfer 
to a human T-cell line by combining 
Sleeping Beauty transposon system 
with methotrexate selection. Biotech-
nol. Bioeng. 2015; 112: 1429–36.
86. Kacherovsky N, Harkey MA, Blau 
CA et al. Combination of Sleeping 
Beauty transposition and chemically 
induced dimerization selection for 
robust production of engineered cells. 
Nucleic Acids Res. 2012; 40: e85.
87. Mezzadra R, Hollenstein A, Go-
mez-Eerland R, and Schumacher TN. 
A Traceless Selection: Counter-se-
lection System That Allows Efficient 
Generation of Transposon and CRIS-
PR-modified T-cell Products. Mol. 
Ther. Nucleic Acids 2016; 5: e298.
88. Moldt B, Yant SR, Andersen PR, 
Kay MA et al. Cis-acting gene reg-
ulatory activities in the terminal re-
gions of sleeping beauty DNA trans-
poson-based vectors. Hum. Gene Ther. 
2007; 18: 1193–204.
89. Heinz N, Schambach A, Galla M et 
al. Retroviral and transposon-based 
tet-regulated all-in-one vectors with 
reduced background expression and 
improved dynamic range. Hum. Gene 
Ther. 2011; 22: 166–76.
90. Najjar AM, Manuri PR, Olivares S et 
al. Imaging of Sleeping Beauty-Modi-
fied CD19-Specific T Cells Expressing 
HSV1-Thymidine Kinase by Positron 
Emission Tomography. Mol. Imaging 
Biol. 2016; 18: 838–848.
91. Kolacsek O, Pergel E, Varga N et al. 
Ct shift: A novel and accurate re-
al-time PCR quantification model for 
direct comparison of different nucle-
ic acid sequences and its application 
for transposon quantifications. Gene 
2017; 598: 43–9.
92. PATENTSCOPE: https://patent-
scope.wipo.int/search/en/search.jsf
93. TargetAMD: http://www.targetamd.
eu
94. Intrexon press release: http://inves-
tors.dna.com/2017-01-10-ZIO-
PHARM-and-Intrex-
on-Announce-Coopera-
tive-Research-and-Develop-
ment-Agreement-with-the-Nation-
al-Cancer-Institute-Utilizing-Sleep-
ing-Beauty-System-to-Gener-
ate-T-cells-Targeting-Neoantigens
95. Ascenion GmbH press release: https://
www.mdc-berlin.de/44841773/en/
news/archive/2015/20150803-for-
mula_pharmaceuticals_and_the_
max_delbr_
96. Ren J, Stroncek DF. Gene ther-
apy simplified. Blood 2016; 128: 
2194–2195.
97. Merck KGaA forges a $941M CAR-T 
development deal with Intrexon: 
http://www.fiercebiotech.com/bio-
tech/updated-merck-kgaa-forges-a-
941m-car-t-development-deal-in-
trexon
98. Yant SR, Ehrhardt A, Mikkelsen JG, 
Meuse L, Pham T, Kay MATransposi-
tion from a gutless adeno-transposon 
vector stabilizes transgene expression 
in vivo. Nat. Biotechnol. 2002; 20, 
999-1005.
99. Zhang W, Solanki M, Muther N et al. 
Hybrid adeno-associated viral vectors 
utilizing transposase-mediated so-
matic integration for stable transgene 
expression in human cells. PLoS One 
2013; 8, e76771.
100. Bowers WJ, Mastrangelo MA, How-
ard DF, Southerland HA, Magu-
ire-Zeiss KA, Federoff HJ. Neuronal 
precursor-restricted transduction via 
in utero CNS gene delivery of a novel 
bipartite HSV amplicon/transposase 
hybrid vector. Mol. Ther. 2006; 13, 
580–8.
101. Peterson EB, Mastrangelo MA, Feder-
off HJ, Bowers WJ. Neuronal speci-
ficity of HSV/sleeping beauty ampl-
icon transduction in utero is driven 
primarily by tropism and cell type 
composition. Mol. Ther. 2007; 15, 
1848–55.
102. De Silva S, Mastrangelo MA, Lotta 
LT Jr, Burris CA, Federoff HJ, Bowers 
WJ. Extending the transposable pay-
load limit of Sleeping Beauty (SB) us-
ing the Herpes Simplex Virus (HSV)/
SB amplicon-vector platform. Gene 
Ther. 2010; 17, 424–31.
103. De Silva S, Mastrangelo MA, Lot-
ta LT Jr et al. Herpes simplex virus/
Sleeping Beauty vector-based embry-
onic gene transfer using the HSB5 
mutant: loss of apparent transposition 
hyperactivity in vivo. Hum. Gene Ther. 
2010; 21: 1603–13.
104. Luo WY, Shih YS, Hung CL et al. 
Development of the hybrid Sleeping 
Beauty-baculovirus vector for sus-
tained gene expression and cancer 
therapy. Gene Ther. 2012; 19: 844–51.
105. Staunstrup NH, Moldt B, Mates L et 
al. Hybrid lentivirus-transposon vec-
tors with a random integration profile 
in human cells. Mol. Ther. 2009; 17: 
1205–14.
106. Intrexon, ZIOPHARM and MD 
Anderson in Exclusive CAR T Pact: 
http://investors.dna.com/2015-01-
13-Intrexon-ZIOPHARM-and-MD-
Anderson-in-Exclusive-CAR-T-Pact
107. Clinical trial database of National 
Institutes of Health: https://clinical-
trials.gov/
CELL & GENE THERAPY INSIGHTS 
158 DOI: 10.18609/cgti.2017.014
108. Yant SR, Park J, Huang Y, Mikkelsen 
JG, Kay MA. Mutational Analysis 
of the N-Terminal DNA-Binding 
Domain of Sleeping Beauty Trans-
posase: Critical Residues for DNA 
Binding and Hyperactivity in Mam-
malian Cells. Mol. Cell Biol. 2004; 24: 
9239-47.
109. Geurts AM, Yang Y, Clark KJ et al. 
Gene transfer into genomes of human 
cells by the sleeping beauty transposon 
system. Mol Ther. 2003; 8:108-17.
110. Hausl MA, Zhang W, Müther N et al. 
Hyperactive Sleeping Beauty Trans-
posase Enables Persistent Phenotyp-
ic Correction in Mice and a Canine 
Model for Hemophilia B. Mol Ther. 
2010; 18:1896-1906.
111. Baus J, Liu L, Heggestad AD, Sanz S, 
Fletcher BS. Hyperactive transposase 
mutants of  the Sleeping Beauty trans-
poson. Mol Ther. 2005; 12:1148-56. 
AFFILIATIONS
Suneel A Narayanavari & Zsu-
zsanna Izsvák*
Max Delbrück Center for Molecular 
Medicine in the Helmholtz Association 
(MDC), Berlin, Germany
 
*Corresponding author: 
zizsvak@mdc-berlin.de
